Is AOD-9604 Legal in Alabama?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone, specifically amino acids 176 to 191. Researchers at Monash University in Australia developed it in the 1990s specifically to isolate the lipolytic properties of growth hormone without raising insulin-like growth factor-1 (IGF-1) levels. That distinction matters clinically: elevated IGF-1 is associated with cell proliferation concerns that have limited therapeutic enthusiasm for full-sequence hGH in metabolic applications.

Mechanism of Action

AOD-9604 appears to stimulate fat breakdown through beta-3 adrenergic receptor pathways and may inhibit lipogenesis. Animal studies published in peer-reviewed endocrinology literature documented dose-dependent reductions in adipose tissue in obese rodent models without the hyperglycemic effects seen with full hGH administration. [1]

The peptide does not bind the growth hormone receptor in the same way as the full 191-amino-acid sequence, which is why researchers pursued it as a targeted anti-obesity compound rather than a general anabolic agent.

The Metabolin Development History

The Australian company Metabolic Pharmaceuticals advanced AOD-9604 through Phase II and Phase III clinical trials under the brand name Metabolin in the early 2000s. A Phase IIb dose-ranging trial (N=300) published results in 2004 showing modest but statistically significant weight loss at the 1 mg oral dose over 12 weeks compared to placebo. [2] The compound received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient in 2014, a designation that relates strictly to food safety and confers no drug approval. [3]

The drug application was ultimately not approved by the FDA as a finished pharmaceutical product. That regulatory gap is the direct reason AOD-9604 now lives in the compounding pharmacy system rather than on a pharmacy shelf.

Federal Legal Framework for AOD-9604

AOD-9604 is not listed as a controlled substance under the Controlled Substances Act (CSA). [4] That means possessing or prescribing it does not carry the federal criminal penalties attached to Schedule I through V substances. What it does carry is a complex patchwork of FDA compounding restrictions that effectively governs whether any given pharmacy can legally make and dispense it.

The 503A vs. 503B Compounding Distinction

The Drug Quality and Security Act of 2013 created two compounding categories under the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional compounding pharmacies that prepare drugs for individual patients based on a valid prescription. Section 503B covers outsourcing facilities that can produce larger batches without patient-specific prescriptions but must register with the FDA and meet Current Good Manufacturing Practice (CGMP) standards. [5]

For peptides specifically, the FDA published a series of guidance documents between 2019 and 2022 placing most bulk peptide substances under heightened scrutiny. The agency's position is that a bulk drug substance may only be used in compounding if it appears on the FDA's 503A bulk ingredients list or, for 503B facilities, on a separate nominated substances list. [6]

AOD-9604 does not currently appear on the FDA's affirmative 503A bulk list. This is the central federal constraint that Alabama patients and prescribers must understand.

What the 2022 FDA Guidance Changed

Before 2022, many 503A compounding pharmacies operated under an informal tolerance, compounding peptides like AOD-9604 without clear FDA objection. The FDA's March 2022 guidance memo on bulk drug substances tightened that window considerably. The guidance clarified that substances not on the affirmative list could face enforcement action if compounded at 503A pharmacies. [6]

503B outsourcing facilities retain somewhat more flexibility because they operate under CGMP oversight and can petition the FDA to add substances to their nominated list. Several 503B facilities have continued to compound AOD-9604 under that framework, though the FDA retains the authority to object at any time.

A practical decision framework for Alabama prescribers and patients:

| Pathway | Permitted? | Key Requirement | |---|---|---| | 503A compounding pharmacy | Restricted; high enforcement risk | AOD-9604 not on affirmative bulk list | | 503B outsourcing facility | Generally available with Rx | CGMP compliance, physician order | | Direct-to-consumer without Rx | No | Alabama Medical Practices Act, FD&C Act | | FDA-approved finished product | Not applicable | No approved product exists | | Research use (IRB-supervised) | Yes | IND application or IRB protocol required |

Alabama State Law and AOD-9604

Alabama does not independently schedule AOD-9604. The Alabama Uniform Controlled Substances Act (Alabama Code Title 20, Chapter 2) adopts federal scheduling by reference and adds specific state-scheduled substances; AOD-9604 appears on neither list. [7] That means state criminal law does not independently prohibit possession or dispensing, but federal compounding rules still apply to any pharmacy operating in or shipping to Alabama.

Alabama Board of Pharmacy Rules

The Alabama State Board of Pharmacy regulates compounding pharmacies under the Alabama Pharmacy Practice Act and follows USP Chapter <797> standards for sterile compounding. [8] Any pharmacy compounding a sterile injectable form of AOD-9604 for Alabama patients must comply with those USP <797> environmental and microbial testing requirements regardless of whether the compounding happens inside or outside the state.

The Board has not issued an AOD-9604-specific advisory as of the date of this article's review. Prescribers and patients should check the Board's current bulletin page for updates, because regulatory postures on compounded peptides have shifted repeatedly since 2020.

Alabama Medical Practices Act and Prescribing Authority

Alabama's Medical Practices Act (Alabama Code Section 34-24-50 et seq.) requires that any prescription medication be ordered by a licensed physician, certified registered nurse practitioner, or physician assistant operating within their scope of practice. [9] A valid physician-patient relationship must exist before a peptide prescription can be issued.

Telehealth prescribing is permitted in Alabama under the Alabama Telehealth Act (Act 2021-272), which means a licensed Alabama physician may evaluate a patient via video and issue a prescription for AOD-9604 through a compliant 503B facility. [10] The physician must be licensed in Alabama, and the patient must be physically located in Alabama at the time of the encounter.

Does Alabama Have Any Additional Peptide Restrictions?

No Alabama statute or Board of Pharmacy rule specifically restricts peptides as a drug class beyond what federal law already requires. The state's Dangerous Drug Act covers substances with significant abuse potential; AOD-9604 has not been classified as a dangerous drug under that act. Alabama follows the FDA's posture closely, so any future federal rescheduling or bulk-list action would effectively bind Alabama practice without any separate state legislative action.

Clinical Evidence Relevant to Prescribers

Understanding the legal framework matters less if the clinical rationale for prescribing is unclear. Alabama physicians who consider prescribing AOD-9604 should have a working familiarity with the existing trial data.

Phase II and Phase III Trial Data

The Phase IIb trial (N=300) evaluated oral AOD-9604 at doses of 0.25 mg, 0.5 mg, 1 mg, and 5 mg daily for 12 weeks in adults with a body mass index between 27 and 35 kg/m². The 1 mg group showed a mean weight loss of 2.8 kg versus 0.8 kg in the placebo group (P<0.001). [2] No serious adverse events were reported at any dose above placebo rates, and IGF-1 levels remained within normal ranges across all treatment arms.

A separate Phase III trial (N=536) tested the 1 mg oral dose for 24 weeks. Results showed a mean weight loss of 3.4 kg versus 1.1 kg placebo. [11] The trial did not meet the pre-specified primary endpoint for regulatory approval in a head-to-head comparison with the effect size needed for the FDA's obesity drug standard at the time.

How AOD-9604 Compares to Approved GLP-1 Agents

For context, the STEP-1 trial (N=1,961) showed semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo. [12] AOD-9604's 3.4 kg absolute loss over 24 weeks is substantially smaller in both absolute and percentage terms. That comparison does not disqualify AOD-9604 from clinical consideration, but it shapes where it fits: current evidence positions it as a supplementary or adjunctive agent rather than a primary weight-loss therapy.

Injectable vs. Oral Formulations in Compounding Practice

Compounding pharmacies that supply AOD-9604 through 503B channels most commonly produce subcutaneous injectable formulations at concentrations ranging from 2 mg/mL to 5 mg/mL, typically dosed at 250 to 500 micrograms per injection. Oral bioavailability data for compounded formulations are sparse; the clinical trials cited above used a proprietary oral delivery system that most compounding pharmacies cannot replicate. Prescribers should account for this when setting patient expectations about efficacy relative to trial data.

How to Get AOD-9604 Legally in Alabama

Obtaining AOD-9604 legally in Alabama requires three things in sequence: a licensed physician's evaluation, a valid prescription, and a 503B-compliant compounding pharmacy that currently compounds the peptide.

Step 1: Physician Evaluation

A board-certified physician, in Alabama or licensed to practice in Alabama via telehealth, must evaluate the patient and determine that AOD-9604 is medically appropriate. Alabama physicians practicing under the state's Medical Practices Act bear full prescribing responsibility. No online platform may dispense AOD-9604 without a genuine physician review.

Step 2: Finding a Compliant 503B Pharmacy

Patients and prescribers can verify 503B outsourcing facility registration through the FDA's public outsourcing facility list at fda.gov. [13] Registered 503B facilities are inspected by the FDA under CGMP standards, which provides a measurably higher quality assurance standard than 503A pharmacies for sterile injectables.

The prescriber or clinic typically establishes a pharmacy relationship on behalf of patients. Patients should ask their clinic to confirm in writing that the pharmacy being used is 503B-registered and that AOD-9604 is currently on that pharmacy's compounded product list.

Step 3: Prescription Transmission and Dispensing

Once the physician issues a prescription, the 503B pharmacy may ship the compounded product directly to the patient in Alabama. Interstate shipping of prescription compounded drugs is lawful under federal law when the dispensing pharmacy is properly licensed in its home state and the receiving state does not have a specific prohibition (Alabama does not). [14]

Alabama patients should never purchase AOD-9604 from websites that sell without requiring a prescription. Those products are not FDA-reviewed, carry unknown purity and potency, and expose the purchaser to legal risk under both federal misbranding laws and Alabama's Dangerous Drug Act.

Risks, Limitations, and What Remains Unknown

AOD-9604's Phase II and Phase III safety data are reassuring within the studied populations and durations. The published trials followed participants for 12 to 24 weeks; no long-term safety data beyond that window exist in peer-reviewed literature. [2, 11]

The FDA has not independently reviewed compounded injectable AOD-9604's pharmacokinetics. Injectable formulations likely differ from the oral formulations studied in trials; the bioavailability and peak concentration profiles may differ enough to change both efficacy and side-effect profiles. Injection-site reactions (erythema, mild swelling) are the most commonly reported adverse effects in clinical settings using injectable formulations, though these are not systematically reported in published literature for the compounded product.

Patients with active malignancy, a history of IGF-1-sensitive tumors, or pregnancy should not use AOD-9604 based on general peptide safety principles and the absence of safety data in those populations. [1]

The FDA's enforcement posture toward 503A peptide compounding has become more active since 2022. Patients who begin a course of AOD-9604 through a legitimate 503B pharmacy should understand that the regulatory environment may shift, potentially affecting supply.